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Abstract
Objective We studied the effect of long-term alglucerase/
imiglucerase (Ceredase®/Cerezyme®, Genzyme, a Sanofi
company, Cambridge, MA, USA) treatment on hematolog-
ical, visceral, and bone manifestations of Gaucher disease
type 1 (GD1).
Methods The International Collaborative Gaucher Group
(ICGG) Gaucher Registry identified GD1 patients treated
with alglucerase/imiglucerase who had dose and clinical
data at first infusion and after 10 years of follow-up. Data
for hemoglobin, platelet count, organ volumes, bone pain,
and bone crisis were analyzed. Tests of the null hypothesis
(no change from first infusion to 10 years) were performed
using t tests for within-patient absolute change in continu-
ous measurements and McNemar/chi-square tests for
change in distributions using categorical values. An alpha
level of 0.05 designated statistical significance.
Results As of October 2011, 557 nonsplenectomized and 200
splenectomized patients met the inclusion criteria. The major-
ity of GD1 patients had at least one N370S allele. Compared
with nonsplenectomized patients at first infusion, splenectom-
ized patients had lower percentages of anemia (26.0 % vs.
42.8 %) and thrombocytopenia (14.2 % vs. 76.3 %), similar
percentages of moderate or severe hepatomegaly (81.2 % vs.
80.0 %), and higher percentages of bone pain (88.9 % vs.
52.4 %) and bone crises (38.3 % vs. 16.0 %). After 10 years,
both groups showed significant (p<0.05) improvements in
mean hemoglobin levels, platelet count, liver, and spleen
(nonsplenectomized) volumes, and bone crises. Initial dosing
in both groups ranged from <15 U/kg to ≤90 U/kg every
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2 weeks. After 10 years, the majority was receiving 15 to ≤45
U/kg every 2 weeks.
Conclusion Ten years of imiglucerase treatment results in
sustainable improvements in all GD1 parameters.
Introduction
Gaucher disease (GD) is an autosomal recessive lysosomal
storage disorder that results from loss of function of acid β-
glucosidase (EC 3.2.1.45; lysosomal glucocerebrosidase)
due to mutations in the glucocerebrosidase gene, GBA1
(Grabowski et al. 2010). Deficient glucocerebrosidase ac-
tivity leads to accumulation of the enzyme’s substrate, glu-
cocerebroside, in tissue macrophages and to displacement of
normal cells in tissues of multiple organs, such as liver,
spleen, and bone marrow (Charrow et al. 2000). Clinical
manifestations of GD include hematological abnormalities
(thrombocytopenia, anemia, leukopenia), splenic and hepat-
ic enlargement (with associated dysfunction), skeletal dis-
ease (chronic bone pain, acute bone crises, defective bone
mineralization, infarction, osteonecrosis, osteolysis, and
pathological fractures) (Charrow et al. 2000; Weinreb et al.
2008), growth retardation (Kaplan et al. 2006), and de-
creased health-related quality of life (HR-QoL) (Weinreb
et al. 2007). The traditional classification of GD recognizes
three clinically distinct forms: type 1 (nonneuronopathic,
OMIM #230800), type 2 (acute neuronopathic, OMIM
#230900), and type 3 (chronic neuronopathic, OMIM
#231000). GD type 1 (GD1) is differentiated from GD2
and GD3 by the absence of overt, early-onset neurological
signs and symptoms (Grabowski et al. 2010). However,
distinct neurological symptoms such as peripheral neuropa-
thy and Parkinson’s disease may occur in GD1 (Biegstraaten
et al. 2008).
GD1 was the first lysosomal storage disease to be suc-
cessfully treated with enzyme therapy, initially in 1991 with
placental-derived glucocerebrosidase, (alglucerase, Cere-
dase®, Genzyme Corporation,1 Cambridge, MA, USA),
and beginning in 1994, with recombinant glucocerebrosi-
dase, (imiglucerase, Cerezyme®, Genzyme). Imiglucerase is
highly effective in reversing visceral and hematologic man-
ifestations of GD as well as some aspects of skeletal disease
(Andersson et al. 2005; Barton et al. 1991; Charrow et al.
2007; Grabowski et al. 1998; Sims et al. 2008; Weinreb et
al. 2008; Weinreb et al. 2002; Wenstrup et al. 2007) over a
wide range of doses (Grabowski et al. 2009).
Evaluation of hematological and organ responses and
skeletal manifestations is the standard minimum criterion
for evaluating efficacy of treatment for GD1 in both clinical
trials and in everyday practice. This report used observa-
tional data from the International Collaborative Gaucher
Group (ICGG) Gaucher Registry to analyze responses of
GD1 patients at first infusion and after 10 years of imiglu-
cerase treatment. We hypothesized that imiglucerase therapy
would demonstrate a sustained benefit, even after 10 years
of treatment.
Materials and methods
International Collaborative Gaucher Group (ICGG) Gaucher
Registry
The ICGG Gaucher Registry was launched in 1991 to track
clinical, demographic, genetic, biochemical, and therapeutic
characteristics of patients with GD throughout the world,
irrespective of disease severity, treatment status, or treat-
ment choice (Charrow et al. 2000). Governance and scien-
tific direction is provided by an international group of
physician experts in GD, with operational support from
Genzyme, a Sanofi company (Cambridge, MA, USA). With
Institutional Review Board (IRB)/Ethics Committee appro-
vals and after obtaining informed patient consent, physi-
cians from 62 countries voluntarily submitted deidentified
data on more than 6,000 patients, capturing 54,000 patient
years of follow-up.
Study population
We identified all GD1 patients in the ICGG Gaucher Reg-
istry as of October 2011 who received imiglucerase (Cere-
zyme®, Genzyme) or alglucerase (Ceredase®, Genzyme),
which are therapeutically equivalent treatments (Grabowski
et al. 1995). In the report presented here, the term imiglu-
cerase is used to denote patients who received either alglu-
cerase or imiglucerase. Inclusion criteria for the study data
set were patients with GD1 who had dose and clinical data
at first imiglucerase infusion (baseline) and after 10 years of
therapy. Within the study cohort, subsets of patients were
identified with clinical data for hemoglobin, platelet count,
liver volume, spleen volume, bone pain, and bone crisis at
treatment initiation (baseline) and after 10 years of follow-
up. Patients without clinical data at baseline and after 10 years
were excluded.
Because splenectomy is known to have an immediate and
persistent influence on GD pathophysiology and patient
phenotype, osteonecrosis (Deegan et al. 2011; Mistry et al.
2009), and hematological response (Cox et al. 2008; Hughes
et al. 2007), data were further analyzed by splenectomy
status. Patients were stratified into nonsplenectomized and
splenectomized groups. Because the postprocedure pheno-
type after partial splenectomy is generally closer to that of1 In 2011, Genzyme Corporation became Genzyme, a Sanofi company.
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patients with fully intact spleens than to those with total
splenectomy, in this treatment response analysis, the small
number of eligible partial splenectomy patients (N027)
were included among the much larger number of patients
with fully intact spleens (N0557).
For this analysis, baseline was defined as a window of
time ranging from 12 months prior to 1 month following the
date of treatment initiation. The 10-year interval was defined
as the time from 9.5 years to 10.5 years. Within each time
window, whenever a patient had more than one clinical
assessment date, the value associated with the date closest
to the date of treatment initiation or the date closest to the
10-year interval was incorporated into the analysis. No data
were included after the Cerezyme manufacturing interrup-
tion (25 June 2009). If patients switched to an alternative
form of enzyme replacement therapy, their data were ex-
cluded from the analysis.
Statistical analysis
Demographics and clinical parameters at treatment initiation
and after 10 years (hemoglobin, platelet count, liver volume,
spleen volume, bone pain, and bone crisis), and frequency
of genotypes were characterized using descriptive statistics.
Organ volumes, measured by magnetic resonance imaging
(MRI), computed tomography (CT), or ultrasound (US), are
reported in multiples of normal (MN) size predicted for
body weight: approximately 2.5 % of body weight for liver,
and 0.2 % for spleen (Elstein et al. 1997; Ludwig 1979).
Clinical parameters were analyzed both as continuous meas-
urements, and as categorical measurements using the fol-
lowing cut points:
& Anemia is defined according to age and gender norms
for hemoglobin concentrations, as follows: <12 g/dl for
males >12 years; <11 g/dl for females >12 years;
<10.5 g/dl for children ages >2–12 years; <9.5 g/dl for
children ages 6 months to 2 years; <10.1 g/dl for chil-
dren younger than 6 months of age.
& Thrombocytopenia is categorized as mild or none
(≥120×103/mm3), moderate (60 to <120×103/mm3), or
severe (<60×103/mm3).
& Splenomegaly (spleen volume in multiples of normal) is
scored as mild or none (≤5), moderate (>5 to ≤15), or
severe (>15).
& Hepatomegaly (liver volume in multiples of normal) is
scored as mild or none (≤1.25), moderate (>1.25 to
≤2.5), or severe (>2.5).
& Bone pain is defined as being present if the patient
reported this event as occurring in the 30-day interval
before the medical visit.
& Bone crisis was defined as present if the patient reported
this event at the time of the medical visit. The ICGG
Gaucher Registry defines bone crisis as: “Pain with acute
onset that requires immobilization of the affected area,
narcotics for the relief of pain, and may be accompanied
by 1 or more of the following: periosteal elevation: elevat-
ed white blood cell count, fever, or debilitation>3 days.”
& Doses used were those reported at first infusion and at
10 years.
For analysis of continuous values, we calculated both the
within-patient absolute change and percentage change from
treatment initiation to 10 years. For categorical analysis, we
produced shift tables representing change in the distribution
of values from first infusion to 10 years. The normality of
the distributions was tested, and paired t tests were per-
formed. Tests of the null hypotheses (i.e. no change from
first infusion to 10 years) were calculated using the paired t
test for the within-patient absolute change in continuous
measurements, the McNemar test for binary variables, and
the chi-square test when a variable had more than two
categories. An alpha level of 0.05 denotes statistical
significance.
Results
As of October 2011, 757 GD1 patients enrolled in the ICGG
Gaucher Registry met the study inclusion criteria of receiv-
ing imiglucerase and having both clinical data and dose data
at first infusion (baseline) and after 10 years of follow-up.
Of these, 226 patients received imiglucerase only, and 531
started treatment with alglucerase and transitioned to imi-
glucerase. Of the overall patient cohort, 200 were splenec-
tomized and 557 were not.
Nonsplenectomized patients
The demographic characteristics of nonsplenectomized
GD1 patients are shown in Table 1. Most patients were
diagnosed early in life (median age at diagnosis: 11 years).
The median age for first imiglucerase infusion was not until
24 years. Genotypes were reported for approximately 89 %
of nonsplenectomized patients (Table 2). Nearly all (92 %)
had at least one N370S allele (27 % homozygous, 65 %
heteroallelic). Among patients with available baseline data,
prior to starting imiglucerase treatment, 42.8 % of nonsple-
nectomized patients were anemic, 76.3 % had moderate or
severe thrombocytopenia, 86.9 % had moderate or severe
splenomegaly, 80.0 % had moderate or severe hepatomega-
ly, 52.4 % reported bone pain, and 16.0 % reported bone
crises (Table 4; Supplementary Figs. 1–6).
Changes in hematological, visceral organ, and skeletal
characteristics reported at first infusion and after 10 years of
treatment are shown in Table 3. For mean hemoglobin
concentration (g/dl), there was a significant improvement
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observed at 10 years (11.2 increased to 13.6; P<0.0001)
compared with the start of treatment. Approximately 88 %
of nonsplenectomized patients who were anemic at first
infusion were no longer so after 10 years of treatment
(Table 4, Supplementary Fig. 1a).
Nonsplenectomized patients had a mean platelet count of
95.3×103/mm3 at first infusion, which improved to a mean of
166.6×103/mm3 after 10 years (P<0.0001) (Table 3). At
10 years, the number of patients with severe thrombocytope-
nia decreased significantly (P<0.001) (Supplementary
Fig. 2a). The 397 patients eligible for platelet response anal-
ysis included 20 with partial splenectomies (5.0 %). Mean
platelet count in these patients improved from 148×103/mm3
at first infusion to 190×103/mm3 after 10 years (data not
shown). Nonsplenectomized GD1 patients (N0107) demon-
strated significant (P<0.0001) improvement in spleen size
over the 10 years of treatment. Mean spleen volume at first
infusion was 19.4 MN and decreased to a mean of 5.2 MN
after 10 years (Table 3). The number of patients with moderate
and severe splenomegaly was significantly lower (P<0.0001)
after 10 years of imiglucerase therapy (Table 4, Supplemen-
tary Fig. 3). Only three partial splenectomy patients had
sufficient data for inclusion in this analysis (mean spleen
volume at first infusion: 9.0 MN; after 10 years: 3.5 MN; data
not shown). There were also significant (P<0.0001) reduc-
tions in liver size over 10 years of treatment (Table 3). At first
infusion, the mean liver volume for nonsplenectomized
patients was 1.8 MN and decreased to 1.0 MN after 10 years.
The numbers of patients with moderate and severe hepato-
megaly decreased significantly (P<0.0001) after 10 years; no
patients had severe hepatomegaly at this time point (Table 4,
Supplementary Fig. 4a).
Imiglucerase treatment positively affected skeletal symp-
toms, as noted by decreased bone pain (Table 4, Supplemen-
tary Fig. 5a) and bone crises (Table 4, Supplementary Fig. 6a).
For nonsplenectomized GD1 patients with bone pain data, 98/
187 (52.4 %) reported bone pain prior to initiation of imiglu-
cerase (Table 4, Supplementary Fig. 5a). Of these, 57.1 % (n0
56) no longer reported bone pain after 10 years of treatment.
Of the 89 patients with no reported bone pain prior to initiation
Table 1 Demographic characteristics of nonsplenectomized and sple-
nectomized patients with type 1 Gaucher disease
Nonsplenectomizeda Splenectomized
Patients Enrolled N0557 N0200
Sex, N (%) N0557 N0200
Males 263 (47) 80 (40)
Females 294 (53) 120 (60)
Age at Diagnosisb (years) N0554 N0196
Median (25th, 75th) 11 (5, 30) 10 (4, 23)
Mean (SD) 18 (16) 15 (13)
Min, Max <0c, 75 0, 53
Age at Diagnosisb, N (%) N0554 N0196
Prenatalc to <10 Years 261 (47) 95 (48)
10 to <20 years 76 (14) 39 (20)
20 to <30 years 81 (15) 33 (17)
30 to <40 years 60 (11) 18 (9)
40 to <50 years 50 (9) 9 (5)
50 to <60 years 20 (4) 2 (1)
60 to <70 years 5 (1) 0
≥70 years 1 (<1) 0
Age at First infusion (years) N0557 N0200
Median (25th, 75th) 24 (9, 42) 38 (26, 49)
Mean (SD) 26 (19) 37 (16)
Min, Max 0, 75 3, 74
Age at Last Follow-up (years) N0557 N0200
Median (25th, 75th) 37 (23, 56) 54 (40, 63)
Mean (SD) 40 (19) 52 (16)
Min, Max 13, 87 18, 87
SD standard deviation
a Includes 27 patients with partial splenectomy
b Patients with no diagnosis date or with diagnosis date earlier than
1 year prior to birth were excluded from the analysis
c Diagnosed prenatally
Table 2 Frequency of genotype categories of nonsplenectomized and
splenectomized patients with type 1 Gaucher disease




N370S/N370S 132 (27) 25 (13)
N370S/L444P 106 (22) 37 (20)
N370S/rare allelea 93 (19) 26 (14)
N370S/?b 52 (11) 27 (14)
N370S/84GG 51 (10) 30 (16)
N370S/IVS2+1 17 (3) 10 (5)
L444P/rare allelea 11 (2) 8 (4)
Rare allelea/rare allelea 11 (2) 10 (5)
L444P/L444P 8 (2) 4 (2)
L444P/?b 3 (1) 7 (4)
D409H/rare allelea 2 (<1) –
? b/? b 2 (<1) 1 (1)
L444P/D409H 1 (<1) –
D409H/D409H 1 (<1) –
84GG/rare allelea 1 (<1) 2 (1)
IVS2+1/rare allelea 1 (<1) 1 (1)
Rare allelea/?b 1 (<1) –
84GG/?b – 1 (1)
a Rare allele is defined as known allele that is not N370S, L444P, IVS2
+1, D409H, or 84GG
bResults of genotype test did not match any tested mutations
c Includes 27 patients with partial splenectomy
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of imiglucerase, 75 (84.3 %) continued to be pain free when
evaluated after 10 years of therapy. For nonsplenectomized
patients with bone crisis data, 27/169 (16.0 %) had a report of
bone crisis prior to initiation of imiglucerase. Of these, 92.6 %
(n025) did not report a bone crisis after 10 years of treatment
(Table 4, Supplementary Fig. 6a). None of the 142 patients
who reported no bone crises prior to initiation of imiglucerase
reported bone crises after 10 years of therapy. At initiation of
treatment (Table 6), most patients were dosed in the middle
range at either >15 to ≤45 U/kg every 2 weeks (n0244
patients, 43.8 %) or >45 to ≤90 U/kg every 2 weeks (n0
198, 35.5 %). A smaller percentage of patients received low
doses (≤15 U/kg every 2 weeks, n0112, 20.1 %) and hardly
any received high doses (>90 to ≤150 U/kg every 2 weeks,
n03, <1 %). After 10 years of imiglucerase, most (82.2 %)
were receiving imiglucerase doses in the middle range (>15 to
≤45 or >45 to ≤90 U/kg every 2 weeks), but now the majority
(57.6 %) were receiving >15 to ≤45 U/kg every 2 weeks,
reflecting shifts away from lower and higher dose groups.
Splenectomized patients
Demographic characteristics of splenectomized patients are
shown in Table 1. As with patients with intact spleens, most
splenectomized patients were diagnosed early in life (medi-
an age at diagnosis 10 years). The splenectomized group
differed from the nonsplenectomized group in having pro-
portionally more females (60 % vs. 53 %, respectively), a
higher proportion of patients diagnosed from 10 to <30 years
(37 % vs. 29 %), and older median ages at first imiglucerase
infusion (38 years vs. 24 years) and at last follow-up
(54 years vs. 37 years). Genotypes were reported for ap-
proximately 95 % of splenectomized patients (Table 2). The
majority (82 %) had at least one N370S allele (13 %
Table 3 Change in clinical parameters from initiation of imiglucerase to 10 years following first infusion in nonsplenectomized and splenectom-
ized patients with type 1 Gaucher disease
Nonsplenectomizeda Splenectomized









No. 376 376 376 131 131 131
Mean (SD) 11.2 (1.7) 13.6 (1.6) 2.4 (1.8) 11.9 (1.7) 13.4 (1.6) 1.5 (1.8)
Median 11.2 13.6 2.4 12.0 13.5 1.4
Min, Max 6.7, 16.2 8.8, 17.9 −3.0, 7.9 6.8, 16.9 6.9, 17.6 −5.0, 7.4
P value* <0.0001 <0.0001
Platelet Count (x 103/mm3)
No. 397 397 397 141 141 141
Mean (SD) 95.3 (52.8) 166.6 (59.7) 71.3 (51.9) 237.8 (125.5) 311.2 (98.3) 73.4 (126.0)
Median 87.0 169.0 71.0 218.0 307.0 68.0
Min, Max 16.0, 448.0 25.0, 433.0 −170.0, 219.0 6.0, 726.0 98.0, 644.0 −329.0, 464.0
P value* <0.0001 <0.0001
Spleen Volume (Multiples of Normal)
No. 107 107 107 – – –
Mean (SD) 19.4 (16.2) 5.2 (3.6) −14.3 (15.0) – – –
Median 15.9 3.7 −10.7 – – –
Min, Max 1.4, 91.8 1.2,15.7 −88.8,1.6 – – –
P value* <0.0001 – – –
Liver Volume (Multiples of Normal)
No. 105 105 105 32 32 32
Mean (SD) 1.8 (0.8) 1.0 (0.2) −0.8 (0.7) 2.2 (1.0) 1.0 (0.24) 1.2 (0.91)
Median 1.7 1.0 −0.7 2.1 0.93 −0.97
Min, Max 0.6, 6.0 0.6, 1.9 −4.5, 0.2 0.7, 4.4 0.7, 1.7 −3.4, 0.1
P value* <0.0001 <0.0001
SD standard deviation
a Includes 27 patients with partial splenectomy
*Tests of the null hypotheses (i.e. no change from first infusion to 10 years) were calculated using the paired t-test for the within-patient absolute change
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homozygous, 69 % heteroallelic) and were less likely to
have N370S homozygosity and more likely to lack an
N370S allele than patients with intact spleens. Prior to
starting imiglucerase treatment, splenectomized patients
had the following clinical status at baseline: 26.0 % were
anemic, 14.2 % had moderate or severe thrombocytopenia,
81.2 % had moderate or severe hepatomegaly, 88.9 %
reported bone pain, and 38.3 % reported bone crises
(Table 5, Supplementary Figs. 1b, 2b, 4b, 5b, 6b).
Compared with the nonsplenectomized group, there was a
lower percentage of patients with anemia (26.0 % vs.
42.8 %) and thrombocytopenia (14.2 % vs. 76.3 %), a
similar percentage with moderate or severe hepatomegaly
(81.2 % vs. 80.0 %), and a higher percentage with bone pain
(88.9 % vs. 52.4 %) and bone crises (38.3 % vs. 16.0 %).
Changes in hematological, visceral organ, and skeletal char-
acteristics for splenectomized patients reported at first infusion
and after 10 years of treatment are shown in Table 3. The
patients demonstrated a significant (P<0.0001) improvement
in mean hemoglobin concentration (g/dl) 10 years following
first infusion (from 11.9 to 13.4). In fact, 91.2% of patients who
were anemic at first infusion were no longer so after 10 years of
treatment (Table 5, Supplementary Fig. 1b). Platelet counts
improved with treatment (mean at baseline 237.8×103/mm3
vs. mean at 10 years 311.2×103/mm3), as it did nonsplenec-
tomized patients (Tables 3 and 5, Supplementary Fig. 2b). The
number of nonsplenectomized patients with severe thrombocy-
topenia decreased significantly (P<0.0001) after 10 years; no
splenectomized patients had severe thrombocytopenia at
10 years (Table 5, Supplementary Fig. 2b). Liver volumes
significantly improved (P<0.001) in splenectomized patients
after 10 years (Table 3), with mean volume decreasing from 2.2
MN to a median of 1.0MN (Table 3). The response was similar
to that of nonsplenectomized patients, who had less hepatomeg-
aly prior to treatment (mean at first infusion 1.8 MN decreased
to a mean of 1.0 MN at 10 years). The percentage of splenec-
tomized patients reporting bone pain at first infusion was
88.9 % (48/54), which decreased to 61.1 % (33/54) after
Table 4 Change in clinical
parameters from initiation of
imiglucerase to 10 years follow-
ing first infusion in non-
splenectomizeda patients with
type 1 Gaucher disease
aIncludes patients with partial
splenectomy
bAnemia is defined according to
age and gender norms for
hemoglobin concentrations,
as follows: <12 g/dl for males
older than 12 years; < 11 g/dl for
females older than 12 years;
< 10.5 g/dl for children ages>
2–12 years; < 9.5 g/dl for children
ages 6 months to 2 years; < 10.1
g/dl for children younger than
6 months
*Tests of the null hypotheses
(i.e., no change from first
infusion to 10 years) were calcu-
lated using the McNemar test
**Tests of the null hypotheses
(i.e., no change from first
infusion to 10 years) were calcu-
lated using the chi- square test
10 years following first infusion, n (%)
First infusion No Yes Total P value*
Anemiab
No 210 (97.7) 5 (2.3) 215 (100) <0.0001
Yes 141 (87.6) 20 (12.4) 161 (100)
Total 351 (93.4) 25 (6.6) 376 (100)
Bone pain during past month
Yes 56 (57.1) 42 (42.9) 98 (100) <0.0001
No 75 (84.3) 14 (15.7) 89 (100)
Total 131 (70.1) 56 (29.9) 187 (100)
Bone crises since last submission
Yes 25 (92.6) 2 (7.4) 27 (100) <0.0001
No 142 (100.0) 0 142 (100)
Total 167 (98.8) 2 (1.2) 169 (100)
10 years following first infusion, n (%)
First infusion Mild Moderate Severe Total P value**
Thrombocytopenia categories
Mild (≥120) 88 (93.6) 6 (6.4) 0 94 (100) <0.0001
Moderate (60 to <120) 175 (81.0) 40 (18.5) 1 (0.5) 216 (100)
Severe (<60) 44 (50.6) 37 (42.5) 6 (6.9) 87 (100)
Total 307 (77.3) 83 (20.9) 7 (1.8) 397 (100)
Splenomegaly
Mild (≤5) 14 (100.0) 0 0 14 (100) <0.0001
Moderate (>5 to ≤15) 31 (83.8) 6 (16.2) 0 37 (100)
Severe (>15) 21 (37.5) 34 (60.7) 1 (1.8) 56 (100)
Total 66 (61.7) 40 (37.4) 1 (0.9) 107 (100)
Hepatomegaly
Mild (≤1.25) 21 (100.0) 0 0 21 (100) <0.0001
Moderate (>1.25 to ≤2.5) 61 (92.4) 5 (7.6) 0 66 (100)
Severe (>2.5) 8 (44.4) 10 (55.6) 0 18 (100)
Total 90 (85.7) 15 (14.3) 0 105 (100)
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10 years (Table 5, Supplementary Fig. 5b). The majority of
patients without bone pain after 10 years were from the
initial subgroup reporting bone pain (18/21, 85.7 %). Ab-
sence of bone pain prior to first infusion was reported for
only six splenectomized patients, three of whom reported
bone pain when evaluated after 10 years. Compared with
nonsplenectomized patients, higher percentages reported
bone pain prior to and after 10 years, irrespective of bone
pain status prior to treatment. Treatment positively affect-
ed the frequency of bone crises in splenectomized patients
(Table 5, Supplementary Fig. 6b), decreasing from 38.3 %
(18/47) to 6.4 % (3/47), all of whom were from the
subgroup reporting bone crises prior to treatment. Similar
to nonsplenectomized patients, at the start of treatment,
the majority of splenectomized patients received imiglu-
cerase in the middle two dose ranges: >15 to ≤45 U/kg
every 2 weeks (N074, 37.0 %); >45 to ≤90 U/kg every 2
weeks (N075, 37.5 %) (Table 6). The remainder (N051,
25.5 %) received low doses (≤15 U/kg every 2 weeks),
and no patient received high doses (>90 to ≤150 U/kg
every 2 weeks). After 10 years, the majority of patients
(N0107, 53.5 %) were receiving imiglucerase doses in the
range of 15 to ≤45 U/kg every 2 weeks, reflecting a shift
from other dose groups. The dose distribution at 10 years
appeared similar to that of nonsplenectomized patients.
Discussion
The focus of this study, which analyzed the responses of
GD1 patients at first infusion and after 10 years of imiglu-
cerase treatment, was to assess whether responses to therapy
were maintained for this time period. Clinical responses,
including the influence of spleen status, were analyzed in a
large cohort of nonsplenectomized (n0557) and splenec-
tomized (n0200) GD1 patients enrolled in the ICGG
Gaucher Registry. The results indicated that all parameters
studied responded favorably to imiglucerase after 10 years
of treatment.
The ICGG Gaucher Registry is a voluntary enterprise,
and all registry data are analyzed retrospectively and unau-
dited by the study authors (Hollak et al. 2011). Data on each
Table 5 Change in clinical
parameters from initiation of
imiglucerase to 10 years follow-
ing first infusion in splenectom-
ized patients with type 1
Gaucher disease
SD standard deviation
aAnemia is defined according to
age and gender norms for hemo-
globin concentrations, as follows:
< 12 g/dl for males >12 years; <
11 g/dl for females >12 years; <
10.5 g/dl for children ages >2 –12
years; < 9.5 g/dl for children ages
6 months to 2 years; < 10.1 g/dl
for children <6 months
*Tests of null hypotheses (i.e.,
no change from first infusion to
10 years) were calculated using
the McNemar test
**Tests of the null hypotheses
(i.e., no change from first infu-
sion to 10 years) were calculated
using the chi-square test
Splenectomized patients
10 years following first infusion, N (%)
First infusion No Yes Total P value* P value**
Anemiaa
No 94 (96.9) 3 (3.1) 97 (100) <0.0001
Yes 31 (91.2) 3 (8.8) 34 (100)
Total 125 (95.4) 6 (4.6) 131(100)
Bone Pain during past month
Yes 18 (37.5) 30 (62.5) 48 (100) 0.0011
No 3 (50.0) 3 (50.0) 6 (100)
Total 21 (38.9) 33 (61.1) 54 (100)
Bone Crises since last submission
Yes 15 (83.3) 3 (16.7) 18 (100) 0.0001
No 29 (100.0) 0 29 (100)
Total 44 (93.6) 3 (6.4) 47 (100)
10 years following first infusion, N (%)
First infusion Mild Moderate Severe Total
Thrombocytopenia (platelet count x 103/mm3)
Mild (≥120) 120 (99.2) 1 (0.8) 0 121 (100) 0.9201
Moderate (60 to <120) 13 (100.0) 0 0 13 (100)
Severe (<60) 7 (100.0) 0 0 7 (100)
Total 140 (99.3) 1 (0.7) 0 141 (100)
Hepatomegaly
Mild (≤1.25) 6 (100.0) 0 0 6 (100) 0.0273
Moderate (>1.25 to ≤2.5) 16 (88.9) 2 (11.1) 0 18 (100)
Severe (>2.5) 4 (50.0) 4 (50.0) 0 8 (100)
Total 26 (81.3) 6 (18.8) 0 32 (100)
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parameter are not available for every patient, but the collec-
tive data set far exceeds any previously described. The ICGG
Gaucher Registry has made diligent efforts to verify data as
complete and accurate. Patients analyzed in this study are
clinically heterogeneous. Once patients have achieved stable
disease parameters, their monitoring investigation schedules
are generally less intensive, and regular organ imaging does
not occur after 8–10 years of treatment, resulting in the rela-
tively small numbers for some parameters in our analysis.
Nevertheless, the ICGG Gaucher Registry offers the possibil-
ity of evaluating a very large sample of patients with GD1.
Although the relationship between long term effective-
ness data and the occurrence of safety and adverse event
data are of interest, these were not included in this analysis
because data collected through Genzyme’s pharmacovigi-
lance system cannot be linked to data in the registry. Safety
and adverse event data among Cerezyme users have been
previously published and reviewed (Starzyk et al. 2007;
Elstein and Zimran 2009).
The patients in this 10-year response study constitute
34.5 % (N0767) of 2,222 registry patients with GD1 with
whom alglucerase or imiglucerase was initiated in 1999 or
earlier (35.9 % of all patients with intact spleens and 29.7 %
of all total splenectomy patients). This study’s patients are
indistinguishable from the larger registry population in
terms of gender, age at diagnosis, and age of first infusion
(Supplementary Table 1). Additionally, regardless of sple-
nectomy status, the difference between age at first infusion
and at last registry data entry for all 2,222 GD1 patients is
10–12 years, suggesting there is little if any selection bias
due to attrition of more severely affected, poorly responding
patients. The lack of relevant data at the prescribed 10-year
data point was the overwhelming reason for exclusion. Of
the 2,222 GD1 patients who began alglucerase/imiglucerase
in 1999 or earlier, 149 died [71 of 1,549 (5 %)] intact spleen;
78 of 673 (12 %) total splenectomy]. The adequacy of
response to treatment in these deceased patients will be
evaluated as part of an in-progress mortality analysis.
Splenectomy influences the degree of cytopenia caused by
hypersplenism (Hughes et al. 2007) is a recognized risk factor
for avascular osteonecrosis (Deegan et al. 2011; Mistry et al.
2009) and is associated with arterial and venous thrombosis
and pulmonary arterial hypertension (Crary and Buchanan
2009). Since the advent of imiglucerase therapy, the need for
splenectomy to control signs and symptoms of GD1, includ-
ing severe cytopenias and abdominal discomfort, has been
substantially reduced (Cox et al. 2008). To account for the
effects of splenectomy on patients with GD1, we analyzed the
cohort in two groups. Similar numbers of patients in both
groups (nonsplenectomized 47%; splenectomized 48%)were
diagnosed with GD1 before 10 years of age. The mean age at
diagnosis for these two groups was 18 and 15 years, respec-
tively, which is similar to some previous registry reports
(Charrow et al. 2000; Weinreb et al. 2002) but younger than
a single-center case series and treatment study (Grabowski et
al. 1995; Zimran et al. 1992). The differences between reports
Table 6 Distribution of dose receiveda at first infusion and at 10 years following first infusion for patients with type 1 Gaucher disease, N (%)
Dosage distribution
Nonsplenectomizedb 10 years following first infusion
First infusion dose received (U/kg every 2 weeks) ≤15 >15 ≤45 >45 ≤90 >90 ≤150 Total P value
≤15 54 (48.2) 46 (41.1) 11 (9.8) 1 (0.9) 112 (100) <0.0001
>15 ≤45 29 (11.9) 154 (63.1) 61 (25.0) 0 244 (100)
>45 ≤90 12 (6.1) 120 (60.6) 63 (31.8) 3 (1.5) 198 (100)
>90 ≤150 0 1 (33.3) 2 (66.7) 0 3 (100)
Total 95 (17.1) 321 (57.6) 137 (24.6) 4 (0.7) 557 (100)
Splenectomized 10 years following first infusion
First infusion dose received (U/kg every 2 weeks) ≤15 >15 ≤45 >45 ≤90 >90 ≤150 Total P value
≤15 22 (43.1) 26 (51.0) 2 (3.9) 1 (2.0) 51 (100) <0.0001
>15 ≤45 9 (12.2) 45 (60.8) 20 (27.0) 0 74 (100)
>45 ≤90 5 (6.7) 36 (48.0) 32 (42.7) 2 (2.7) 75 (100)
>90 ≤150 0 0 0 0 0
Total 36 (18.0) 107 (53.5) 54 (27.0) 3 (1.5) 200 (100)
a Frequencies and percentages along the diagonal self-explanatory--> represent patients whose dose group did not change from first infusion to
10 years following initiation of therapy. Those above the diagonal indicate patients whose dose increased, and those below the diagonal patients
whose dose decreased
b Includes 27 patients with partial splenectomy
*Tests of the null hypotheses (i.e., no change from first infusion to 10 years) were calculated using the chi-square testtable–>
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may be due to local genotypic and diagnostic differences, or
alternatively, possible selection and reporting bias of registry
data (Rothman 2002).
After 10 years of imiglucerase, approximately 90 % of all
patients who were anemic at first infusion had normalized
hemoglobin levels. We were unable to determine from the
registry data whether anemia at the 10-year point was due to
refractory GD or some alternative etiology. At this same
time point, >90 % (6/7) of patients who had severe throm-
bocytopenia at first infusion had improved platelet counts.
Despite consistent improvements in thrombocytopenia in
patients with intact spleens, proportionately fewer patients
had normal platelet counts after 10 years of treatment than
patients who had normal hemoglobin concentrations. This
observation is consistent with earlier studies of imiglucerase
(Weinreb et al. 2002), velaglucerase (Zimran et al. 2010),
and taliglucerase (Zimran et al. 2011) and is attributable to
multiple possible causes. These causes include differences
in platelet and red blood cell (RBC) kinetics; different
pooling mechanisms in the spleen; different control mecha-
nisms in the marrow and marrow microenvironment for
erythropoiesis and thrombopoiesis, chronic platelet activa-
tion, and consumption due to bone disease; differences in
the effect of changes in plasma volume on RBC versus
platelet concentrations in peripheral blood; presence of anti-
platelet antibodies in some patients; and different sensitivity
of RBC and platelets to reduction in spleen size (Hollak et
al. 2012). All splenectomized patients with thrombocytope-
nia at first infusion had normal counts at 10 years. The
enhanced response in splenectomy patients also reflects
previous experience and likely reflects the major contribu-
tion of the spleen to the thrombocytopenia due to GD and
the relative ease of reversibility of depressed thrombopoiesis
in GD-infiltrated marrow. Of patients with severe spleno-
megaly at first infusion, 97 % had decreased spleen volumes
after 10 years. Similar results were reported for liver vol-
umes: all patients who had severe hepatomegaly at first
infusion had decreased liver volumes after 10 years.
Genotypes of most of GD1 patients in this study were
N370S homozygous or heterozygous, with one of the fol-
lowing mutations: L444P, rare allele, 84GG, or IVS2+1.
Whereas the L444P/L444P genotype was reported in a few
patients (8/493 nonsplenectomized; 4/189 splenectomized),
all of those patients were reported by their physicians as
having a GD1 phenotype.
Pretreatment hematological and visceral organ abnormali-
ties reported in this study were generally similar to those
previously reported by Charrow et al. (2000). Although blood
and visceral organ abnormalities are potentially important
contributors to morbidity in patients with GD1, hepatospleno-
megaly and hematological cytopenias are generally correct-
able, save for a relatively small number of patients with
pretreatment complications, such as fibrotic spleen or liver
fibrosis and portal hypertension. On the other hand, skeletal
manifestations associated with untreated GD1 have the poten-
tial to cause long-term disability and negatively impact the
patient’s quality of life permanently (Weinreb et al. 2007). In
this study, by the time treatment was begun, bone pain was
reported by the majority of nonsplenectomized (98/187) and
nearly all splenectomized (48/54) patients. Bone crises, which
often signal irreversible osteonecrosis, were reported not only
in splenectomized (18/47) patients, but also in those with
intact spleens (27/169). The percentage of splenectomized
patients with bone pain and bone crises was approximately
twice that of nonsplenectomized patients (89 % vs 52 % and
38 % vs 16 %, respectively). Because of the inevitable occur-
rence of irreversible damage, delay in initiating treatment in
patients with bone complications is, as we found, likely to be
reflected in a poorer long-term response and clinical outcome.
Previous reports (Grabowski et al. 1998; Pastores et al.
1993; Weinreb et al. 2002) describe the effects of alglucerase/
imiglucerase treatment after 6 months to 5 years. Pastores et al.
(1993) and Weinreb et al. (2002) reported improvements in all
hematological and visceral organ parameters within the first
6 months to 2 years of therapy. Specifically, Weinreb et al.
(2002) reported that patients with anemia achieved normal
hemoglobin levels within 2 years of starting imiglucerase, and
hemoglobin levels were sustained or increased during the initial
5 years of therapy. In nonsplenectomized patients, the level of
platelet response was associated with degree of thrombocyto-
penia (Weinreb et al. 2002), presence of focal splenic defects
(Stein et al. 2010), and dose of imiglucerase (Grabowski et al.
2009). Generally, platelet counts increased during the first
2 years of treatment and continued to improve through 5 years
(Weinreb et al. 2002). Similarly, Weinreb et al. (2002) reported
decreased spleen and liver volumes with imiglucerase treat-
ment: spleen volumes decreased for the first 2 years, whereas
reductions in liver volume may continue to year 5 (Weinreb et
al. 2002). Weinreb et al. (2002) noted that liver volumes gen-
erally normalized, but decreases in spleen volume to less than
five times normal rarely occurred.
A previous report (Wenstrup et al. 2007) indicated that
skeletal manifestations, including bone density, took longer
(≥8 years) to respond to imiglucerase than other hematolog-
ical and visceral organ manifestations of GD1. Many
patients in our study responded positively to imiglucerase
treatment, as noted by reported reductions in bone crises and
bone pain. Of the nonsplenectomized patients reporting pain
at first infusion, 93 % (25/27) and 57 % (56/98) reported no
bone crises nor bone pain, respectively, after 10 years. De-
creased bone pain and bone crisis have been reported after
the first year of imiglucerase treatment (Charrow et al. 2007;
El-Beshlawy et al. 2006; Weinreb et al. 2002). Of the
splenectomized patients reporting pain at first infusion, after
10 years, 38 % (18/48) reported no bone pain and 83 % (15/
18) no bone crises. Splenectomy has been reported to be a
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risk factor for the skeletal manifestations of GD1 (Deegan et
al. 2011; Mistry et al. 2009). An interval of ≥2 years be-
tween diagnosis and initiation of imiglucerase therapy was
associated with a higher risk of severe skeletal complication
of avascular osteonecrosis (Mistry et al. 2009). It is possible
that other skeletal complications are also related to the time
between diagnosis and the start of therapy.
Reports of bone pain to the registry might not necessarily
be attributable to GD and may not necessarily be reversible. In
addition, it may either be overreported to the registry as limb
pain not emanating from bony complications, or misreported
as skeletal involvement not related to GD. Similarly, bone
crises may be exaggerated if the definition is not strictly
adhered to by registry physicians. Such variations may have
occurred at first infusion and 10 years after imiglucerase
treatment. Because our analysis focused on only two points
over a 10-year observation period (first infusion and 10 years),
bone pain results may not accurately portray the patient’s
chronic state. Despite this possible reporting bias, there was
a decrease in bone pain and bone crisis symptoms after
10 years of therapy. Nevertheless, some patients with chronic
bone pain may continue to be symptomatic even after years of
therapy. Some of these patients may potentially benefit from
modern, expert orthopedic interventions.
The clinical responses reported in this study were ob-
served over a broad range of imiglucerase doses at initiation
of therapy and at the 10-year period. Response to imiglucer-
ase is statistically related to treatment dose (Grabowski et al.
2009; Wenstrup et al. 2007), although clinically, patients
responded over a wide range of doses. In general, after
10 years of therapy, biweekly dose was reduced compared
with initial dose. Patients may change dose over time for a
number of reasons, including adequate response, compli-
ance, and enzyme availability.
In summary, improvements in hematological, visceral, and
bone manifestations previously reported after short-term imi-
glucerase therapy were maintained after 10 years of treatment
in nonsplenectomized and splenectomized patients with GD1.
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